B

Beeline Medicines

Clinical-stage biotech developing precision autoimmune therapies

Medical Science Liaison

Full-TimeUpdated on 10/23/2026
No salary listed
Mid, Senior
PharmD, PhD, MD
Japan
In PersonField-based within the assigned territory; regular travel is required, and travel may exceed 50%.
Biology & Biotech

About the job

Requirements
  • An advanced degree (PharmD, PhD, or MD) in a relevant life sciences, pharmacy, or biomedical field is required.
  • At least 3 years of MSL or related field-based medical affairs experience in pharmaceutical or biotech; the Senior MSL role requires at least 5 years of MSL or field-based medical affairs experience.
  • Developing scientific and clinical knowledge of immunology and inflammation, including disease mechanisms, treatment landscapes, and emerging therapeutic approaches.
  • Ability to interpret and communicate clinical and scientific data, including study design, statistical concepts, and benefit-risk assessment, in peer-to-peer settings.
  • Working proficiency in CRM platforms such as Veeva for field activity documentation, stakeholder mapping, and territory management.
  • Knowledge of medical affairs compliance frameworks, including FDA and EMA regulations, PhRMA guidelines, and on-label versus off-label scientific exchange.
  • Ability to manage territory priorities, engagement calendars, and field activities with increasing independence; the Senior MSL role requires full strategic independence.
  • Ability to present and discuss company data clearly and accurately with healthcare professionals, key medical experts, and investigators.
  • Ability to capture field insights and clinical practice observations accurately and translate them into concise internal communications.
  • Professional fluency in written and spoken English.
  • Ability to safely operate a motor vehicle; a valid driver's license and a driving record meeting company standards are required.
  • Willingness and ability to travel 50% or more as needed, including occasional overnight stays.
  • Ability to work evenings and weekends as needed for physician or patient events.
  • Depending on geography, ability to manage a multi-state territory with a diverse customer base.
Responsibilities
  • Contribute to medical strategy development and refinement using field insights and engagement with healthcare professionals, key medical experts, and investigators.
  • Develop and execute territory plans aligned with organizational priorities and data milestones.
  • Develop and manage relationships with key medical experts and healthcare professionals in the immunology and inflammation therapeutic area, identifying and engaging scientific thought leaders, clinical investigators, and relevant academic centers under Medical Affairs leadership.
  • Develop stakeholder segmentation, strategic engagement plans, and ongoing relationships with healthcare professionals, key medical experts, and investigators.
  • Conduct compliant, scientifically rigorous peer-to-peer scientific exchange, sharing clinical and preclinical data, presenting pipeline updates, and discussing unmet medical needs.
  • Support clinical trial awareness and site identification by engaging potential investigators and academic institutions; facilitate discussions supporting site initiation and enrollment, and serve as the sponsor's scientific resource to site investigators from start-up through study closeout in collaboration with Clinical Operations.
  • Respond to unsolicited medical information requests in partnership with Medical Information and in accordance with regulatory and compliance guidelines.
  • Support investigator-initiated study processes by facilitating scientific discussions with healthcare professionals, key medical experts, and investigators and coordinating with Medical Affairs leadership.
  • Identify evidence gaps and contribute to evidence-generation strategies.
  • Synthesize and communicate field insights, competitive intelligence, clinical practice trends, and unmet-need observations as timely, structured recommendations to Medical Affairs, Clinical Development, and cross-functional teams.
  • Represent the company at scientific conferences, medical congresses, and advisory board meetings, engaging scientific thought leaders and gathering information to inform medical and pipeline strategy.
  • For the Senior MSL role, manage a strategic territory of senior key opinion leaders, clinical investigators, and academic centers; develop individualized engagement plans and refine territory strategy based on data milestones, influence mapping, and clinical development priorities.
  • For the Senior MSL role, conduct sophisticated scientific exchange with senior thought leaders, investigators, and healthcare professionals, including discussion of emerging clinical data, benefit-risk considerations, and evolving disease paradigms.
  • For the Senior MSL role, support clinical trials through investigator identification, scientific site engagement, and enrollment strategy discussions with Clinical Development and Clinical Operations.
  • For the Senior MSL role, own investigator-initiated study relationships in the territory, act as the primary scientific contact, facilitate review, and maintain engagement with funded sites.
  • For the Senior MSL role, present strategic engagement insights and field intelligence to leadership and strategy teams, and demonstrate impact on key Medical Affairs priorities, trial enrollment, site activation, and strategic decisions.
  • For the Senior MSL role, contribute to scientific training materials, field tools, and disease-area resources to strengthen the MSL team's capabilities and field effectiveness.
  • For the Senior MSL role, represent the company at major national and international conferences, advisory boards, and key opinion leader forums; contribute to advisory board development, including expert identification, agenda design, and synthesis of outcomes into recommendations.
  • Perform other duties and responsibilities as assigned.
Desired Qualifications
  • Postdoctoral training, clinical fellowship, or residency in a relevant discipline is strongly preferred.
  • Experience in immunology, inflammation, or a related therapeutic area is strongly preferred for the MSL role; demonstrated expertise in immunology, inflammation, or a closely related area is preferred for the Senior MSL role.
  • Clinical-stage biotech experience is a plus.
  • Prior involvement in investigator-initiated study management or clinical trial support is preferred for the Senior MSL role.

About the company

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million.
  • FDA Fast Track for afimetoran in May 2025 accelerates regulatory interaction.
  • Management plans several clinical starts within 12 months, expanding catalysts beyond lupus.

What critics are saying

  • Afimetoran’s Phase 2 lupus readout in H2 2026 is the company’s make-or-break catalyst.
  • Failure versus Benlysta, Saphnelo, and competing lupus drugs kills the pivotal plan.
  • Five BMS-origin assets concentrate scientific risk; one bad readout can crush financing appetite.

What makes Beeline Medicines unique

  • BMS licensed five programs to Beeline in 2025, de-risking discovery.
  • Afimetoran targets TLR7/8, an upstream lupus mechanism unlike downstream cytokine biologics.
  • Saqib Islam and SpringWorks veterans bring repeatable biotech execution and exit experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Health Insurance
  • Company Equity
  • Performance Bonus

Growth & Insights and Company News

6 month growth

-3%

1 year growth

-3%

2 year growth

-3%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...